List of Excipients in Branded Drug ZIRGAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	ZIRGAN	ganciclovir	24208-535	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	ZIRGAN	ganciclovir	24208-535	CARBOMER HOMOPOLYMER TYPE B
Bausch & Lomb Incorporated	ZIRGAN	ganciclovir	24208-535	MANNITOL
Bausch & Lomb Incorporated	ZIRGAN	ganciclovir	24208-535	SODIUM HYDROXIDE
Bausch & Lomb Incorporated	ZIRGAN	ganciclovir	24208-535	WATER

ZIRGAN Excipient Strategy and Commercial Opportunities in Ganciclovir Ophthalmic Gel

Last updated: August 2, 2026

ZIRGAN is ganciclovir ophthalmic gel 0.15%, an antiviral ophthalmic product approved for acute herpetic keratitis caused by herpes simplex virus in adults and children age 2 years and older. Its formulation uses carbomer 974P as the gel-forming polymer and benzalkonium chloride at 0.075% as the preservative.[1] The main commercial opportunity is not a conventional active-ingredient innovation. It is a formulation and packaging strategy focused on reducing preservative exposure, improving ocular comfort, extending residence time, and creating differentiated generic or lifecycle products.

The product’s core formulation is technically reproducible, which supports conventional generic entry. Commercial differentiation is more likely through preservative-free packaging, alternative polymers, improved drop delivery, lower-viscosity formulations, or combination products than through a simple copy of the reference formulation.

What is ZIRGAN and how does its formulation work?

ZIRGAN contains ganciclovir at 0.15% in an ophthalmic gel vehicle. The gel increases ocular residence time compared with a conventional aqueous eye drop, allowing the active ingredient to remain on the corneal surface longer.[1]

Product attribute	ZIRGAN information
Active ingredient	Ganciclovir
Strength	0.15% ophthalmic gel
Dosage form	Topical ophthalmic gel
Approved indication	Acute herpetic keratitis
Approved population	Adults and children age 2 years and older
Original NDA	NDA 022211
FDA approval	2009
Gel-forming excipient	Carbomer 974P
Preservative	Benzalkonium chloride, 0.075%
Other formulation components	Purified water and sodium hydroxide
Commercial company identified in labeling	Bausch & Lomb Incorporated
Primary formulation function	Prolonged ocular contact and topical delivery

The product is applied frequently during the initial treatment phase and less frequently during the maintenance phase. The prescribing information instructs patients to apply one drop five times daily until the corneal ulcer heals, followed by one drop three times daily for seven days.[1]

What excipients are used in ZIRGAN?

ZIRGAN uses a short excipient system with four principal functional components.

Carbomer 974P

Carbomer 974P is the main viscosity-building and mucoadhesive excipient. It is a cross-linked polyacrylic acid polymer used to convert an aqueous ganciclovir solution into a gel.

Its commercial functions include:

• Increasing ocular surface residence time.
• Reducing drainage through the nasolacrimal duct.
• Supporting sustained exposure between doses.
• Improving the feasibility of topical delivery for a poorly retained aqueous solution.

The polymer’s concentration, neutralization level, molecular weight distribution, particle size, and manufacturing process can materially affect viscosity and product performance. These parameters create potential formulation-control and process-control opportunities even when the active ingredient is off patent.

Benzalkonium chloride

Benzalkonium chloride is used as a preservative at 0.075%.[1] It supports multidose packaging by controlling microbial contamination after the container is opened.

The preservative also creates the clearest formulation opportunity. Repeated exposure to benzalkonium chloride can cause ocular-surface irritation, epithelial effects, and tolerability concerns, particularly in patients with frequent dosing or pre-existing ocular-surface disease.[2] A competing product that removes benzalkonium chloride while maintaining sterility, stability, dose accuracy, and bioequivalence could have a meaningful commercial position.

Sodium hydroxide

Sodium hydroxide is used to adjust the formulation’s pH after polymer dispersion and active-ingredient incorporation. Carbomers require neutralization to develop viscosity. The amount of sodium hydroxide therefore affects both pH and gel structure.

A generic manufacturer cannot treat sodium hydroxide as an incidental component. Changes in neutralization can alter:

• Viscosity.
• Drop size.
• Spreadability.
• Ocular comfort.
• Ganciclovir stability.
• Release from the gel matrix.
• Container-drug interaction.

Purified water

Purified water is the continuous phase. Water quality, bioburden control, conductivity, and manufacturing conditions affect product consistency and microbial control.

What formulation patents or intellectual-property barriers protect ZIRGAN?

The commercial barrier around ZIRGAN is more likely to involve formulation know-how, regulatory exclusivity, trademarks, and product-specific manufacturing controls than a currently dominant composition-of-matter patent.

Ganciclovir is an established antiviral compound. The principal IP value in ZIRGAN is associated with topical ophthalmic delivery, gel rheology, preservative use, packaging, and product performance. A company evaluating entry should separate four IP categories:

IP category	Relevance to ZIRGAN
Ganciclovir composition patents	Likely limited commercial importance because ganciclovir is an old active ingredient
Ophthalmic gel formulation patents	May cover polymer systems, viscosity, pH, stability, or delivery performance
Method-of-use patents	Could address herpetic keratitis treatment, dosing, or patient subgroups
Manufacturing and packaging know-how	Can remain commercially important even without broad patent protection

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivities associated with an approved NDA.[3] A current Orange Book review should be performed against NDA 022211 before a paragraph IV filing, because listed patents can change through delisting, expiration, or regulatory updates.

A prospective generic sponsor would also need to evaluate whether its product uses the same qualitative and quantitative excipient composition. Differences in carbomer grade, preservative concentration, pH, viscosity, osmolality, or container closure may increase the regulatory burden.

When did ZIRGAN lose exclusivity and what generic entry risks exist?

ZIRGAN’s original FDA approval occurred in 2009. Any five-year new chemical entity exclusivity associated with the NDA would have expired years ago. The more relevant entry question is patent status and the availability of an ANDA pathway.

For a conventional generic, the principal regulatory route would generally be an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act if the product can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[4]

Potential entry risks include:

1. Listed formulation or method-of-use patents.
2. Difficulty demonstrating equivalent ophthalmic gel performance.
3. Differences in preservative concentration or polymer grade.
4. Container-closure sterility requirements.
5. Dose-delivery differences caused by gel rheology.
6. FDA requests for comparative studies if the formulation is materially different.
7. Commercial substitution challenges if prescribers prefer preservative-free products or established brands.

A product that removes benzalkonium chloride or uses a materially different gel system may not fit cleanly within a simple ANDA strategy. Depending on the degree of difference, the sponsor could face a 505(b)(2) pathway rather than a standard ANDA pathway.[5]

What is the Orange Book status of ZIRGAN?

The relevant reference listed drug is ZIRGAN ophthalmic gel 0.15%, associated with NDA 022211. FDA’s Orange Book identifies approved drug products, patent listings, and exclusivity information where applicable.[3]

A patent certification strategy would depend on the current Orange Book record:

Certification pathway	Commercial implication
Paragraph I	No relevant patent information is listed
Paragraph II	Listed patent has expired
Paragraph III	Applicant waits until listed patent expiration
Paragraph IV	Applicant asserts that the patent is invalid, unenforceable, or not infringed

A paragraph IV filing could trigger patent litigation under the Hatch-Waxman framework and, if suit is filed within the statutory period, a potential 30-month stay of final FDA approval.[4] The commercial timing would depend on the patents listed on the filing date, the litigation outcome, and any settlement agreement.

No biosimilar pathway is relevant. ZIRGAN is a small-molecule ophthalmic drug, not a biologic. Competition would come from ANDA products, 505(b)(2) products, compounded alternatives, and other topical antiviral therapies.

What formulation opportunities exist for ZIRGAN competitors?

Preservative-free ganciclovir gel

A preservative-free product is the strongest obvious differentiation strategy. It could target patients with ocular-surface sensitivity, frequent dosing, contact-lens-related concerns, or chronic ophthalmic treatment exposure.

The principal technical challenge is packaging. A preservative-free multidose bottle requires a validated microbial-barrier system, such as:

• One-way valve technology.
• Metered-dose delivery.
• Airless packaging.
• Sterile unit-dose containers.
• Specialized tip and closure systems.

Packaging may create enforceable IP and a commercial barrier even when the formulation itself is not highly novel.

Lower-benzalkonium formulations

A lower-preservative version could reduce irritation while retaining multidose convenience. The sponsor would need to establish microbial effectiveness and product stability at the lower concentration. A lower concentration could also affect regulatory comparability and would not necessarily qualify as a straightforward generic.

Alternative gel polymers

Potential alternatives to carbomer 974P include other carbomer grades, hydroxypropyl methylcellulose, hypromellose, hydroxypropyl cellulose, poloxamers, hyaluronic-acid-based systems, and in situ gelling polymers.

Each alternative changes the product’s performance profile. Key development targets include:

• Equivalent or improved ocular retention.
• Reduced blurring after administration.
• Lower stringiness and residue.
• Controlled drop size.
• Acceptable release kinetics.
• Comparable ganciclovir exposure.
• No increased corneal toxicity.

Hyaluronic-acid-based systems could offer a comfort-oriented positioning, but they may produce a different viscosity and release profile from carbomer gels.

In situ gelling systems

An in situ gel is administered as a lower-viscosity drop and thickens after contact with the ocular surface. This approach could improve ease of instillation while preserving residence time.

Potential triggers include pH, ionic strength, temperature, or interaction with tear fluid. The commercial advantage would be a better balance between retention and visual clarity. The regulatory burden would be higher because the dosage form and in-use behavior differ from the reference gel.

Unit-dose delivery

Unit-dose packaging could eliminate preservatives and improve sterility control. The drawback is higher packaging cost, increased material use, and less convenient storage for a treatment requiring frequent daily administration.

This strategy may be most attractive for premium products, hospital channels, ophthalmology practices, and patients with significant ocular-surface disease.

How strong is the ZIRGAN formulation patent estate?

The formulation patent estate should be viewed as moderate rather than automatically strong. The active ingredient is old, and the product uses conventional ophthalmic excipients. A broad claim covering ganciclovir in an ophthalmic gel could face validity and prior-art challenges.

The stronger potential claim areas are narrower:

• Specific carbomer grades and concentration ranges.
• Defined pH and viscosity windows.
• Ganciclovir stability in a particular polymer system.
• Preservative concentration and antimicrobial performance.
• Container-closure combinations.
• Manufacturing sequences that control polymer hydration and neutralization.
• Product performance linked to corneal residence time or dosing frequency.

Narrow formulation claims can still delay entry if they are listed in the Orange Book and survive litigation. They may be easier to design around than composition-of-matter claims.

Which companies are challenging ZIRGAN?

The competitive field includes generic ophthalmic manufacturers with sterile topical manufacturing capacity, specialty ophthalmology companies, and developers of preservative-free delivery systems. Potential participants include companies with existing ophthalmic portfolios and access to:

• Sterile liquid and semisolid manufacturing.
• Ophthalmic container-closure systems.
• Carbomer and polymer formulation expertise.
• ANDA regulatory capabilities.
• Commercial distribution through ophthalmology and retail pharmacy channels.

A verified list of active paragraph IV challengers, filed ANDAs, litigation defendants, or settlement parties requires a current FDA, court docket, and Orange Book review. Those records determine whether a named company has an active legal challenge rather than merely a marketed ganciclovir product.

How does ZIRGAN compare with other ocular antiviral opportunities?

Opportunity	Active ingredient	Dosage form	Main differentiation
ZIRGAN	Ganciclovir	Ophthalmic gel	Established topical gel for herpetic keratitis
Acyclovir ophthalmic product	Acyclovir	Ointment or other topical form, depending on market	Alternative antiviral delivery
Trifluridine ophthalmic solution	Trifluridine	Aqueous solution	Established antiviral, generally associated with frequent dosing
Valacyclovir oral therapy	Valacyclovir	Oral tablet	Systemic administration and different exposure profile
Next-generation topical antiviral	Various	Gel, solution, or insert	Potential for improved dosing, comfort, or resistance profile

ZIRGAN’s advantage is a recognized gel dosage form with less frequent maintenance dosing than some older topical antiviral regimens. Its weakness is the preservative burden, treatment frequency, and limited indication scope.

What commercial opportunities exist for ZIRGAN-related products?

The most credible opportunities are:

1. A lower-cost ANDA product using a formulation close to the reference product.
2. A preservative-free ganciclovir gel using unit-dose or multidose preservative-free packaging.
3. A comfort-focused gel with reduced blur and improved spreadability.
4. A pediatric-oriented delivery system with better dose control.
5. A hospital or ophthalmology-channel product supplied in sterile unit doses.
6. A 505(b)(2) product with a differentiated polymer or dosing regimen.
7. A regional licensing deal for formulation technology, packaging, or sterile ophthalmic manufacturing.
8. A combination or adjunctive product strategy for patients with recurrent ocular herpes, subject to clinical and regulatory feasibility.

Revenue exposure is likely concentrated in the ophthalmic antiviral segment rather than the broader antiviral market. Public company reporting generally does not isolate ZIRGAN revenue, so product-specific sales cannot be reliably calculated from consolidated disclosures.[6]

What manufacturing and geographic barriers affect ZIRGAN competition?

Manufacturing barriers are meaningful but manageable. The product requires sterile ophthalmic processing, validated aseptic filling, polymer dispersion control, preservative effectiveness testing, and container-closure integrity testing.

Geographic commercialization also matters. A product approved in the United States may require separate registrations in Europe, Canada, Japan, and other markets. The regulatory classification of ganciclovir gel, preservative requirements, approved indication, and reference-product framework can differ by jurisdiction.

A company with an existing sterile ophthalmic facility has a structural advantage. Licensing opportunities may therefore center on contract manufacturing, regional commercialization, or acquisition of an approved ophthalmic platform rather than on the active pharmaceutical ingredient.

Key Takeaways

• ZIRGAN is ganciclovir ophthalmic gel 0.15%, approved for acute herpetic keratitis.
• Its principal excipients are carbomer 974P, benzalkonium chloride at 0.075%, sodium hydroxide, and purified water.
• Carbomer 974P provides gel structure and increased ocular residence time.
• Benzalkonium chloride is the clearest target for formulation differentiation.
• Preservative-free packaging is the strongest commercial opportunity.
• A conventional ANDA is most feasible for a formulation closely matching the reference product.
• Material changes to the polymer, preservative system, packaging, or dosage form may support a 505(b)(2) strategy.
• The key IP risks are formulation, packaging, method-of-use, and manufacturing claims rather than ganciclovir composition claims.
• ZIRGAN has no biosimilar risk because it is a small-molecule drug.
• Product-specific revenue is not separately disclosed in public company reporting.

FAQs About ZIRGAN Excipient and Commercial Strategy

Can benzalkonium chloride be removed from ZIRGAN?

Yes, but removal requires a new microbial-control and packaging strategy. A preservative-free multidose system or sterile unit-dose container would likely be necessary.

Is carbomer 974P essential to ZIRGAN?

Carbomer 974P is the reference product’s gel-forming polymer, but alternative polymers may be possible. The substitute must deliver comparable viscosity, ocular residence, stability, release, and tolerability.

Could a preservative-free ZIRGAN product obtain ANDA approval?

It may not qualify as a straightforward pharmaceutical equivalent if the formulation and packaging materially differ. The regulatory pathway would depend on FDA’s assessment of the product’s sameness and performance.

Does ZIRGAN have biosimilar competition?

No. ZIRGAN contains ganciclovir, a small-molecule active ingredient. Competition would involve generics or 505(b)(2) products.

What is the most defensible patent position for a new ganciclovir ophthalmic product?

The strongest potential position would likely combine a specific polymer and pH range with a defined viscosity profile, stability data, and a specialized preservative-free container-closure system.

References

1. U.S. Food and Drug Administration. (2022). ZIRGAN (ganciclovir ophthalmic gel) prescribing information. Bausch & Lomb Incorporated.
2. U.S. Food and Drug Administration. (2017). Ophthalmic drug products for over-the-counter human use: Guidance for industry.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format.
5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2): Guidance for industry.
6. Bausch Health Companies Inc. (2023). Annual report and Form 10-K.